Quinupristin/dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium

Clinical Infectious Diseases

Volumn 30, Issue 5, 2000, Pages 790-797

  Winston, Drew J ^a   Emmanouilides, Christos ^a   Kroeber, Anna ^a   Hindler, Janet ^a   Bruckner, David A ^a   Territo, Mary C ^a   Busuttil, Ronald W ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS FAECIUM; ERADICATION THERAPY; FEMALE; HUMAN; MALE; MORTALITY; MYALGIA; PRIORITY JOURNAL; SUPERINFECTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS; ANTIBIOTICS, COMBINED; CHILD; CHILD, PRESCHOOL; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMAN; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 0033801915     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313766     Document Type: Article

References (48)

1. Antimicrobial-drug resistance
2. National Nosocomial Infection Surveillance (NNIS) System. Nosocomial vancomycin resistant enterococci (VRE) in the United States, 1989-1995: The first 1000 isolates
3. Enterococci resistant to multiple antimicrobial agents, including vancomycin: Establishment of endemicity in a university medical center
4. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections
5. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection
6. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit
7. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients
8. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality
9. Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci
10. The challenge of vancomycin-resistant enterococci: A clinical and epidemiologic study
11. Natural history of colonization with vancomycin-resistant Enterococcus faecium
12. Vancomycin-resistant enterococcal bacteremia: Natural history and attributable mortality
13. Bloodstream infections with vancomycin-resistant enterococci
14. Vancomycin-resistant enterococci
15. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections
16. An old antibiotic for a new multiple-resistant Enterococcus faecium?
17. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium
18. Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin
19. Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium
20. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate
21. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium
22. An analysis of treatment of patients with vancomycin-resistant enterococcal bacteremia
23. Quinupristin/dalfopristin: Spectrum of activity, pharmacokinetics, and initial clinical experience
24. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci
25. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United states and their susceptibility in vitro to dalfopristin-quinupristin
26. Enterococcus
27. Vancomycin-resistant enterococci
28. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. Faecium
29. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: Comparison with a control cohort
30. Efficacy and toxicity of Synercid (quinupristin/dalfopristin) for vancomycin-resistant Enterococcus faecium infection
31. Efficacy and safety of quinupristin/dalfopristin (RP59500 Synercid) in the treatment of vancomycin-resistant Enterococcus faecium (VREF) infections
32. Enterococcal bacteremia: Analysis of 75 episodes
33. Enterococcal bacteremia: To treat or not to treat, a reappraisal
34. Risk factors for mortality associated with enterococcal bloodstream infections
35. Enterococcal bacteremia in the surgical intensive care unit: Does vancomycin resistance affect mortality?
36. Enterococcus faecium bacteremia: Does vancomycin resistance make a difference?
37. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes
38. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia
39. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy
40. Emergence of superinfection with Enterococcus faecalis during RP 59500 treatment of vancomycin-resistant Enterococcus faecium infection (VREF)
41. Characterization of arthralgias/myalgias associated with quinupristin/dalfopristin (Synercid)
42. Open comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 95900, Synercid) in subjects with hepatic cirrhosis and healthy volunteers
43. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
44. Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin
45. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium
46. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative